—
C+
C+ The full Closelook — membership. Open the C+ overview

Alkermes Plc (ALKS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Alkermes Plc

ALKS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Alkermes develops and sells drugs for opioid dependence, alcohol dependence, schizophrenia and bipolar disorder, with an injectable suspension, an oral antipsychotic and a narcolepsy treatment among its marketed products. It also licenses manufacturing and delivery technology to other drugmakers and holds collaboration agreements with a major pharmaceutical partner. The company is headquartered in Dublin and lists its shares in the United States.
Where it sits in the stack
Alkermes carries no seat in our Rubin or Halo indices, so it sits only in the diary's broader Healthcare sleeve for US-listed names, outside the AI build-out stack entirely.
Who it is priced against
Closelook's peer group places it among scored Healthcare names based in the United States, including Regeneron, Vertex, BeiGene and Corcept Therapeutics, reflecting shared sector and country rather than shared therapy area.
Why Closelook tracks it
It carries a Closelook score with momentum as its strongest module and valuation as its weakest; it holds no seat in our indices and has not yet drawn a mention in the diary's editions.
What the diary watches
Whether commercial uptake of its newer products offsets pressure on older ones as patents and competition narrow their contribution over time.

Alkermes Plc (ALKS) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 53/100 composite (momentum 75, quality 51, valuation 23) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ALKS, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ALKS on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 31 m USD in FY2025

Dividends and capital return

What ALKS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 31 m USD 0.4% of today's market value
  • Share count −0.3% in FY2025 99 m USD of stock-based compensation in the year
  • Capital returned 31 m USD · 6% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in US: +0.7% week · +0.4% month · +10.2% quarter · +6.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Alkermes Plc (ALKS)?

Alkermes Plc trades as ALKS on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is ALKS in a Closelook index?

Not currently — Alkermes Plc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Alkermes Plc's Closelook composite score?

53 out of 100, with momentum 75, quality 51 and valuation 23 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ALKS trade against its moving averages?

Pullback inside an uptrend stack: Trades -5.3% vs the 50-day and +21.7% vs the 200-day average, 16.1% below the 52-week high and +73.1% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Alkermes Plc do?

Alkermes develops and sells drugs for opioid dependence, alcohol dependence, schizophrenia and bipolar disorder, with an injectable suspension, an oral antipsychotic and a narcolepsy treatment among its marketed products. It also licenses manufacturing and delivery technology to other drugmakers and holds collaboration agreements with a major pharmaceutical partner. The company is headquartered in Dublin and lists its shares in the United States. Closelook's peer group places it among scored Healthcare names based in the United States, including Regeneron, Vertex, BeiGene and Corcept Therapeutics, reflecting shared sector and country rather than shared therapy area.

Where does Alkermes Plc sit in the AI build-out?

Alkermes carries no seat in our Rubin or Halo indices, so it sits only in the diary's broader Healthcare sleeve for US-listed names, outside the AI build-out stack entirely. It carries a Closelook score with momentum as its strongest module and valuation as its weakest; it holds no seat in our indices and has not yet drawn a mention in the diary's editions.

Does Alkermes Plc pay a dividend?

No cash distribution shows in Alkermes Plc’s price series over the last three years. In fiscal 2025 the company bought back 31 m USD of its own shares, 6% of that year’s free cash flow. The share count fell 0.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ALKS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.